GlassScriptPhysician profile
Schon Thomas Knowles
NPI 1023797081
$1,458.44
in general payments reported to CMS, 2019-2025
24 companies · $711 in 2025
The $711 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $748 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $265.05 | 2024-2025 | |
| Indivior INC. | $200.96 | 2024-2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $149.80 | 2024-2025 | Trintellix |
| Lundbeck LLC | $148.18 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $146.80 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Grifols USA, LLC | $82.89 | 2024-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $74.19 | 2024 | Auvelity |
| Viiv Healthcare Company | $46.69 | 2024 | Apretude |
| Exact Sciences Corporation | $36.67 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Alkermes, INC. | $34.73 | 2025 | Aristada, Lybalvi |
| Novo Nordisk INC | $33.45 | 2024-2025 | Wegovy |
| Tris Pharma INC | $30.74 | 2024 | Dyanavel Xr |
| Corium, LLC | $24.96 | 2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.23 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $22.97 | 2024 | Farxiga |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $20.28 | 2025 | Sucraid |
| Organon LLC | $16.31 | 2025 | Nexplanon |
| Neurocrine Biosciences, INC. | $15.74 | 2024 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $14.52 | 2024 | |
| Boston Scientific Corporation | $14.27 | 2025 | Wavewriter Alpha Prime 16 |
| Teva Pharmaceuticals USA, INC. | $14.09 | 2025 | Uzedy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.00 | 2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $13.63 | 2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $13.29 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Schon Knowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.